Autoimmune disease Archives

lupus neovacs stellar limpet protein autoimmune immunotherapy biotech

News and Trends 21 Jan 2016

Fighting Lupus with an Autoimmune Disease Vaccine that Uses Limpet Proteins

Neovacs in Paris (France) investigates immunotherapies for the treatment of autoimmune diseases and today signed a partnering agreement with the molluscan protein manufacturer, Stellar Biotechnologies (US). This joint venture will operate under the name of Neostell SAS, and it will be owned 30:70, the majority going to Neovacs. Neovacs is a biotech focused on an active immunotherapy technology platform (Kinoids) […]

January 21, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 3 Dec 2015

Meet the Company Fighting Autoimmune Diseases with a Novel Immunotherapy

BIO-Europe 2015 was a good opportunity for us to meet people who are playing a key role in the Biotech industry. I had the opportunity to meet Miguel Sieler, CEO of Neovacs, a company that can potentially be the first to develop a therapeutic vaccine for lupus patients! Neovacs is a French biotechnology company developing […]

December 3, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

Apitope relocates to Wales after €12M series B financing round

Now, as we’ve recently discussed here at Labiotech, there doesn’t appear to be many Welsh biotechs…however, this is all about to change, with major Autoimmune disease focused Apitope relocating it’s HQ to Wales. This is following a €12M series B fundraiser led by the Wales Lifesciences Fund for its monoclonal antibody pipeline. Aptiope are currently […]

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 30 Jul 2015

UCB’s Lupus treatment breaks down in Phase III

Big disappointment for Belgian UCB. After 9 years of research, its lead candidate in Immunology, designed to treat Systemic Lupus Erythematosus, failed in Phase III. The drug was acquired from Immunomedics in 2006 and costed at least $38M. Epratuzumab is a monoclonal antibody for the treatment of Systemic Lupus Erythematosus, developed by Immunomedics. For the […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Jul 2015

Biogen is back home with its $1Bn Swiss production plant

Biogen is coming back home. The American company is opening a production plant in Switzerland that will employ 400 professionals. To this aim, the company will invest €0.9Bn ($1Bn) into the project. Biogen was founded back in 1978 in Geneva, Switzerland, and now aims at expanding its manufacturing network by opening a biopharmaceutical plant in […]

July 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Jul 2015

Green light for one of the largest clinical trials in Immunotherapy

In a period, where uncountable big pharmas and biotechs are struggling to get the largest piece of the immunotherapy cake, an unexpected player has arrived. TxCell, a French biotech, received an option to extend its current phase IIb study from EU to US, a stage that lots of immunotherapy experts would like to reach. TxCell was founded fourteen years […]

July 1, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Apr 2015

Synthetic sea anemone’s peptide to cure Autoimmune Diseases

Kineta and researchers from the University of Groningen, Netherlands, announced new data from a study that showed dalazatide (formerly ShK-186) is effective in immunomodulating the cells causing inflammation and damage of small blood vessels in various organs in samples from patients with Granulomatosis with Polyangiitis (GPA). The data were presented at the 17th International ANCA […]

April 22, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 5 Mar 2015

Baxter’s Bioscience Business Acquires SuppreMol

Baxter has acquired SuppreMol for €200M before working capital and other adjustments. The acquisition includes SuppreMol’s early-stage development portfolio of novel biologic immunoregulatory therapeutics for the treatment of autoimmune diseases. SuppreMol is a privately held biopharmaceutical company based in Martinsried, Germany developing treatment options for autoimmune and allergic diseases, focusing on the modulation of Fc […]

March 5, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 19 Feb 2015

Lead Pharma partners with Sanofi to beat Autoimmune Diseases

Lead Pharma is a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer. It has entered into a research collaboration with big-shot Sanofi to develop small molecule therapies directed against the nuclear hormone receptor ROR gamma t (RORyt) to treat a broad range of autoimmune disorders. A big news for this Netherland-based Biotech […]

February 19, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us